Literature DB >> 14647403

Evaluation of the carcinogenic effects of furazolidone and its metabolites in two fish species.

A Auro1, H Sumano, L Ocampo, A Barragán.   

Abstract

The major metabolite from the use of furazolidone (FZD) in mammals, birds and fish is 2,3-dihydro-3-cyanomethyl-2-hydroxy-5-nitro-1alpha, 2-di(2-oxo-oxazolidin-3-yl)iminomethyl-furo[2,3-beta]furan, also called 3-amine-2-oxazolidone (AOZ). A minor metabolite was identified as N-(5-amine-2-furfuryliden)-3-amine-2-oxazolidone (FOZ). To assess the potential carcinogenicity of FZD and the metabolic mixture of AOZ/FOZ, 11 mg FZD/kg feed/day was fed for 12 weeks to mollies (Poecilia formosa), an ornamental fish species prone to develop tumors. The rate of tumors was quantified and defined both in mollies and their offspring. Then, some fish was made into fishmeal and incorporated into fish food at 500 g of meal/kg of food and fed to other mollies for 12 weeks. The rate of tumors was assessed. A similar trial design was carried out in tilapia fish (Oreochromis niloticus) by adding 50 mg FZD/kg to the feed for 90 days. All animals were placed in glass fishponds under controlled laboratory conditions. Each week, a significant biomass was collected from both groups to assess the macroscopic and histopathological changes. All mollies developed melanohistiocytomic tumors in the liver and other organs. Offspring from surviving mollie females stimulated to breed showed no changes compared to control animals. None of the mollies fed with the mollie-meal food contaminated with AOZ/FOZ developed tumors. Neither tilapia medicated with FZD nor tilapia fed with tilapia-meal contaminated with AOZ/FOZ developed tumors. These results do not support the established viewpoint that FZD must be banned from trophic chains based on its potential carcinogenic properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647403     DOI: 10.1038/sj.tpj.6500216

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  2 in total

1.  Furazolidone and Helicobacter pylori Treatment.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Middle East J Dig Dis       Date:  2015-04

2.  Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Authors:  Muhammad Miftahussurur; Hafeza Aftab; Pradeep Krishna Shrestha; Rabi Prakash Sharma; Phawinee Subsomwong; Langgeng Agung Waskito; Dalla Doohan; Kartika Afrida Fauzia; Yoshio Yamaoka
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-15       Impact factor: 4.887

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.